US008361468B2 (12) United States Patent (10) Patent N0.: US 8,361,468 B2 Whitfeld et a1. (45) Date of Patent: *Jan. 29, 2013 (54) HUMANIZED ANTI-CSAR ANTIBODIES 2005/0084906 A1 4/2005 Goetsch 2010/0129346 A1 5/2010 Mackay 2011/0190477 A1 8/2011 Whitfeld et al. (75) Inventors: Peter Whitfeld, Surry Hills (AU); David Zahra, West Pennant Hills (AU); FOREIGN PATENT DOCUMENTS Charles Reay Mackay, Vaucluse (AU) EP 0377489 7/1990 EP 0586505 3/1994 (73) Assignee: G2 In?ammation Pty Ltd, Darlinghurst JP 8109200 4/1996 (AU) W0 W0 9100360 1/1991 W0 W0 9220373 11/1992 W0 W0 9407921 4/ 1994 ( * ) Notice: Subject to any disclaimer, the term of this W0 W0 9411026 5/1994 patent is extended or adjusted under 35 W0 W0 9420142 9/1994 U.S.C. 154(b) by 0 days. W0 W0 9500164 1/1995 W0 W0 9639511 12/1996 This patent is subject to a terminal dis W0 W0 9824893 6/1998 claimer. W0 W0 9833908 8/1998 W0 W0 9844001 10/1998 W0 W0 0238767 5/2002 (21) Appl.No.: 13/590,016 W0 WO 02059263 8/2002 W0 WO 02061087 8/2002 (22) Filed: Aug. 20, 2012 W0 WO 03027252 4/2003 W0 WO 03062278 7/2003 W0 WO 2004040000 5/2004 (65) Prior Publication Data W0 WO 2005060739 7/2005 US 2012/0315275 A1 Dec. 13,2012 W0 WO 2008022390 2/2008 W0 WO 2008022391 2/2008 OTHER PUBLICATIONS Related US. Application Data U.S. Appl. No. 13/525,092, ?led Jun. 15,2012, Mackay. Barry, et al. (1994) “Sequencing and Modeling of Anti-DNA (63) Continuation of application No. 12/866,009, ?led as Immunoglobulin Fv Domains. Comparison With Crystal Structures” application No. PCT/AU2009/000184 on Feb. 19, .1. Biol. Chem. 269(5):3623-3632. Berman, et a1. (1988) “Lymphocyte Motility and Lymphocyte 2009, noW Pat. No. 8,268,972. Chemoattractant Factors” Immunol. Invest. 17(8-9):625-677. (60) Provisional application No. 61/066,539, ?led on Feb. Cain, et al. (2001) “Mapping the Ligand-Binding Site on the C5a 20,2008. Receptor: Arginine74 of C5a Contacts Aspartate282 of the C5a Receptor” Biochemistry 40(46): 14047-14052. Cain, et al. (2001) “Modulation of Ligand Selectivity by Mutation of (51) Int. Cl. the First Extracellular Loop of the Human C5a Receptor” Biochem. A61K39/395 (2006.01) Pharmacol. 61(12):1571-1579. C07K16/28 (2006.01) Caldas, et al. (2000) “Design and Synthesis of Germline-Based c12/v5/10 (2006.01) Hemi-Humanized Single-Chain Fv against the CD18 Surface Anti (52) US. Cl. ............. .. 424/144.1; 424/130.1; 424/133.1; gen” Protein Eng. 13(5):353-360. 424/141.1; 424/143.1; 424/152.1; 424/172.1; Caldas, et al. (2003) “Humanization of the Anti-CD18 Antibody 6.7: 424/173.1; 530/387.1; 530/388.1; 530/388.2; An Unexpected Effect of a Framework Residue in Binding to Anti gen” Mol. Immunol. 39(15):941-952. 530/388.22; 435/326; 435/332; 435/334; Caron, et al. (1992) “Engineered Humanized Dimeric Forms of IgG 435/343; 435/343.1 Are More Effective Antibodies” J'. Exp. Med. 176(4): 1191-1 195. (58) Field of Classi?cation Search ...................... .. None Casset, et al. (2003) “A Peptide Mimetic of anAnti-CD4 Monoclonal See application ?le for complete search history. Antibody by Rational Design” Biochem. Biophys. Res. Commun. 307(1):198-205. (56) References Cited Charlton et al. (1999) “The Expression of CSA Receptor (CSAR) (CD88) Is Associated With the Progression of In?ammation in U.S. PATENT DOCUMENTS Human Disease” J'. Pathol. 187(Suppl.):36A. 3,850,752 A 11/1974 Schuurs et al. (Continued) 3,901,654 A 8/1975 Gross 4,098,876 A 7/1978 Piasio et a1. Primary Examiner * Phillip Gambel 4,676,980 A 6/1987 Segal et a1. (74) Attorney, Agent, orFirm * Carol L. Francis; Bozicevic, 4,704,362 A 11/1987 Itakura et a1. Field & Francis LLP 5,194,594 A 3/1993 Khawli et a1. 5,284,746 A 2/ 1994 Sledziewski et a1. (57) ABSTRACT 5,304,489 A 4/1994 Rosen 5,354,678 A 10/1994 Lebkowski et al. The present invention is directed to humanized antibodies 5,480,974 A 1/1996 Morgan et al. Which bind the human C5a receptor and their use as thera 5,741,957 A 4/1998 Deboer et a1. peutic and diagnostic agents. The present invention is further 5,849,992 A 12/1998 Meade et a1. directed toWard nucleic acid sequences Which encode said 5,861,272 A 1/1999 Li et a1. humanized antibodies, and their expression in recombinant 8,007,798 B2 8/2011 Ashkenazi et al. 8,071,096 B2 12/2011 Mackay host cells. In particular, the present invention is directed 8,071,839 B2 12/2011 Mackay toWards humanized antibodies derived from murine antibody 8,221,757 B2 7/2012 Mackay 7F3 Which speci?cally binds to the human C5a receptor. 8,268,972 B2 * 9/2012 Whitfeld et a1. ....... .. 530/38822 2003/0113798 A1 6/ 2003 Burmer et al. 22 Claims, 37 Drawing Sheets US 8,361,468 B2 Page 2 OTHER PUBLICATIONS Kavanaugh, et al. (1991) “Role of CD11/CD18 in Adhesion and Chen, et al. (1995) “Enhancement and Destruction of Antibody Func Transendothelial Migration of T Cells. Analysis Utilizing CD18 tion by Somatic Mutation: Unequal Occurrence Is Controlled by V De?cient T Cell Clones” J. Immunol. 146(12):4149-4156. Konteatis, et al. (1994) “Development of C5a Receptor Antagonists. Gene Combinatorial Associations” EMBO J. 14(12):2784-2794. Differential Loss of Functional Responses” J. Immunol. Chothia & Lesk (1987) “Canonical Structures for the Hypervariable 153(9):4200-4205. Regions of Immunoglobulins” J. Mol. Biol. 196(4):901-917. Kouskoff, et al. (1996) “Organ-Speci?c Disease Provoked by Sys Chothia, et al. (1989) “Conformations of Immunoglobulin temic Autoimmunity” Cell 87(5):811-822. Hypervariable Regions” Nature 342(6252):877-883. Kozlov, et al. (2004) “Ef?cient Strategies for the Conjugation of Co, et al. (1992) “Chimeric and Humanized Antibodies with Speci Oligonucleotides to Antibodies Enabling Highly Sensitive Protein ?city for the CD33 Antigen” J. Immunol. 148(4): 1 149-1 154. Detection” Biopolymers 73(5): 62 1 -630. Colman (1994) “Effects of Amino Acid Sequence Changes on Anti Kussie, et al. (1994) “A Single Engineered Amino Acid Substitution Changes Antibody Fine Speci?city” J. Immunol. 152(1): 146-152. body-Antigen Interactions” Res. Immunol. 145(1):33-36. Kyburz & Corr (2003) “The KRN Mouse Model of In?ammatory Crass, et al. (1999) “Chimeric Receptors of the Human C3a Receptor Arthritis” Springer Semin. Immunopathol. 25(1):79-90. and C5a Receptor (CD88)” J. Biol. Chem. 274(13):8367-8370. Lebkowski, et al. (1988) “Adeno-Associated Virus: AVector System Crass, et al. (1999) “Receptor Activation by Human C5a des Arg74 for Ef?cient Introduction and Integration of DNA into a Variety of but Not Intact C5a Is Dependent on an Interaction between Glu199 of Mammalian Cell Types” Mol. Cell. Biol. 8(10):3988-3996. the Receptor and Lys68 of the Ligand” Biochemistry 38(30):9712 Lee, et al. (2002) “Mast Cells: A Cellular Link between Autoantibod 9717. ies and In?ammatory Arthritis” Science 297(5587): 1689-1692. Curiel, et al. (1992) “High-Ef?ciency Gene Transfer Mediated by Lee, et al. (2006) “Human CSaR Knock-In Mice Facilitate the Pro Adenovirus Coupled to DNA-Polylysine Complexes” Hum. Gene duction and Assessment of Anti-In?ammatory Monoclonal Antibod Ther 3(2): 147-154. ies” Nat. Biotechnol. 24(10):1279-1284. Dahinden, et al. (1994) “Monocyte Chemotactic Protein 3 Is a Most Lowenstein, et al. (2006) “Different Mechanisms of Campath-1H Effective Basophil- and Eosinophil-Activating Chemokine” J. Exp. Mediated Depletion for CD4 and CD8 T Cells in Peripheral Blood” Med 179(2):751-756. Transplant International 19(11):927-936. Dai, et al. (1992) “Gene Therapy via Primary Myoblasts: Long-Term MacCallum, et al. (1996) “Antibody-Antigen Interactions: Contact Expression of Factor IX Protein Following Transplantation In Vivo” Analysis and Binding Site Topography” J. Mol. Biol. 262(5):732 Proc. Natl. Acad. Sci. USA 89(22):10892-10895. 745. DeMartino, et al. (1995) “Arginine 206 of the C5a Receptor Is Criti Martin, et al. (1989) “Modeling Antibody Hypervariable Loops: A cal for Ligand Recognition and Receptor Activation by C-Terminal Combined Algorithm” Proc. Natl. Acad Sci. USA 86(23):9268 Hexapeptide Analogs” J. Biol. Chem. 270(27): 15966-15969. 9272. Eigenbrot, et al. (1993) “X-ray Structures of the Antigen-Binding Mayo & Curnutte (1990) “Kinetic Microplate Assay for Superoxide Domains from Three Variants of Humanized Anti-p185HER2 Anti Production by Neutrophils and Other Phagocytic Cells” Methods body 4D5 and Comparison with molecular Modeling” 1. Mol. Biol. Enzymol. 186:567-575. 229(4):969-995. Monk, et al. (1995) “Mutation of Glutamate 199 ofthe Human C5a Elsner, et al. (1994) “C3a Activates the Respiratory Burst in Human Receptor De?nes a Binding Site for Ligand Distinct from the Recep Polymorphonuclear Neutrophilic Leukocytes via Pertussis Toxin tor N Terminus” J. Biol. Chem. 270(28): 16625-16629. Sensitive G-Proteins” Blood 83(11):33224-3331. Monk, et al. (2007) “Function, Structure and Therapeutic Potential of Extended European Search Report for European Application No. Complement C5a Receptors” Br. J. Pharmacol. 152(4):429-448. 100090604, dated Jul. 29, 2011. Morgan, et al. (1993) “Anti-C5a Receptor Antibodies. Characteriza Farkas, et al. (1999) “C5a Receptor Expression by TGW tion of Neutralizing Antibodies Speci?c for a Peptide, C5aR-(9-29), Neuroblastoma Cells” Neuroreport 10(14):3021-3025. Derived from the Predicted Amino-Terminal Sequence of the Human Fayyazi et al. (2000) “The C5a Receptor Is Expressed in Normal C5a Receptor” J. Immunol. 151(1):377-388. Renal Proximal Tubular but Not in Normal Pulmonary or Hepatic Murdoch & Finn (2000) “Chemokine Receptors and Their Role in Epithelial Cells” Immunology 99(1):38-45. In?ammation and Infectious Diseases” Blood 95(10):3032-3043. Fitzgerald (1987) “Construction of Immunotoxins Using Needleman & Wunsch (1970) “A General Method Applicable to the Pseudomonas Exotoxin A” Methods Enzymol. 151 : 139-145. Search for Similarities in the Amino Acid Sequence of Two Proteins” Gerard & Gerard (1991) “The Chemotactic Receptor for Human C5a J. Mol. Biol. 48(3):444-453. Anaphylatoxin” Nature 349(6310):614-617. Neote, et al. (1993) “Molecular Cloning, Functional Expression, and Gerard & Gerard (1994) “C5A Anaphylatoxin and Its Seven Signaling Characteristics of a C-C Chemokine Receptor” Cell Transmembrane-Segment Receptor” Annu. Rev. Immunol. 12:775 72(3):415-425. 808. Niemeyer, et al. (2003) “Combination of DNA-Directed Immobili Gerber, et al. (2001) “An Activation Switch in the Ligand Binding zation and Immuno-PCR: Very Sensitive Antigen Detection by Pocket of the C5a Receptor” J. Biol. Chem. 276(5):3394-3400. Means of Self-Assembled DNA-Protein Conjugates” Nucl. Acids Hansen & Balthasar (2002) “Intravenous Immunoglobulin Mediates Res. 31(16):e90. an Increase in Anti-Platelet Antibody Clearance via the FcRn Recep Nisihara, et al. (2001) “Humanization and Epitope Mapping of Neu tor” Thromb. Haemost. 88(6):898-899. tralizing Anti-Human Fas Ligand Monoclonal Antibodies: Structural Hendrickson, et al. (1995) “High Sensitivity Multianalyte Insights into Fas/Fas Ligand Interaction” J. Immunol. 167(6):3266 Immunoassay Using Covalent DNA-Labeled Antibodies and 3275. Polymerase Chain Reaction” Nucleic Acids Res. 23(3):522-529. Oppermann, et al. (1993) “Probing the Human Receptor for C5a Jagels, et al. (1996) “Proteolytic Inactivation of the Leukocyte C5a Anaphylatoxin with Site-Directed Antibodies. Identi?cation of a Receptor by Proteinases Derived from Porphyromonas Gingivalis” Potential Ligand Binding Site on the NH2-Terminal Domain” J. Infect. Immun. 64(6): 1984-1991. Immunol. 151(7):3785-3794. Ji, et al. (2002) “Arthritis Critically Dependent on Innate Immune Pease, et al. (1994) “Generation of Chimeric C5a/Formyl Peptide System Players” Immunity 16(2): 157-168. Receptors: Towards the Identi?cation of the Human C5a Receptor Jones, et al. (1986) “Replacing the Complementarity-Determining Binding Site” Eur J. Immunol. 24(1):211-215. Regions in a Human Antibody with Those from a Mouse” Nature Pellas, et al. (1998) “Novel C5a Receptor Antagonists Regulate 321(6069):522-525. Neutrophil Functions In Vitro and In Vivo” J. Immunol. Jose, et al. (1994) “Eotaxin: A Potent Eosinophil Chemoattractant 160(11):5616-5621. Cytokine Detected in a Guinea Pig Model of Allergic Airways Preithner, et al. (2006) “High Concentrations of Therapeutic IgGl In?ammation” J. Exp. Med 179(3):881-887. Antibodies Are Needed to Compensate for Inhibition of Antibody Kaneko, et al. (1995) “Antagonistic Peptides against Human Dependent Cellular Cytotoxicity by Excess Endogenous Anaphylatoxin C5a” Immunology 86(1): 149-154. Immunoglobulin G” Mol. Immunol. 43(8): 1183-1 189. US 8,361,468 B2 Page 3 Proctor, et al. (2006) “Recent Developments in C5/C5a Inhibitors” Wu, et al. (1999) “Humanization of a Murine Monoclonal Antibody Expert Opinion on Therapeutic Patents 16(4):445-458. by Simultaneous Optimization of Framework and CDR Residues” .I. Pulito, et al. (1996) “Humanization and Molecular Modeling of the Mol. Biol. 294(1):151-162. Anti-CD4 Monoclonal Antibody, OKT4A” .I. Immunol. Zachariae, et al. (1990) “Properties of Monocyte Chemotactic and 156(8):2840-2850. Activating Factor (MCAF) puri?ed from a Human Fibrosarcoma Queen, et al. (1986) “Cell-Type Speci?c Regulation of a Kappa Cell Line” J. Exp. Med. 171(6):2177-2182. Immunoglobulin Gene by Promoter and Enhancer Elements” Biomarkers De?nitions Working Group (2001) “Biomarkers and surrogate endpoints: preferred de?nitions and conceptual frame Immunol. Rev. 89:49-68. Raffetseder, et al. (1996) “Site-Directed Mutagenesis of Conserved wor ” Clin Pharmacol Ther 69(3):89-95. Champtiaux & Changeux (2002) “Knock-out and knock-in mice to Charged Residues in the Helical Region of the Human C5a Receptor. investigate the role of nicotinic receptors in the central nervous sys Arg206 Determines High-Af?nity Binding Sites of C5a Receptor” tem” Curr Drug Targets CNS Neurol Disord 1(4):319-330. Eur. J. Biochem. 235 (1-2):82-90. Drago (2003) “Neuronal nicotinic receptors: insights gained from Rothermel, et al. (2000) “Analysis of the Tissue Distribution of the gene knockout and knockin mutant mice” Cellular Mol Life Sci Rat C5a Receptor and Inhibition of C5a-Mediated Effects through 60(7):1267-1280. the Use of Two MoAbs” Scand. J. Immunol. 52(4):401-410. Dymecki, Susan M., Flp recombinase promotes site-speci?c DNA Rudikoff, et al. (1982) “Single Amino Acid Substitution Altering recombination in embryonic stem cells and transgenic mice., Proc Antigen-Binding Spec”Proc. Natl. Acad. Sci. USA 79(6): 1979-1983. Natl Acad Sci U S A. Jun. 11, 1996;93(12):6191-6196. Sayah, et al. (1999) “Expression of Cytokines by Human Examiner’s Report issued by Australian Patent Of?ce dated Dec. 22, Astrocytomas Following Stimulation by C3a Anaphylatoxins: Spe 2011, AU Patent Application No. 2007288188 (3 pages). ci?c Increase in Interleukin-6 mRNA Expression” .I. Neurochem. Gerard et al. (1993) “Human chemotaxis receptor genes cluster at 72(6):2426-2436. 19q13.3-13.4. Characterization of the human C5a receptor gene” Schlaf, et al. (1999) “Differential Expression of the C5a Receptor on Biochemistry 32(5): 1243-1250. the Main Cell Types of Rat Liver as Demonstrated with a Novel Girardi (2003) “Complement C5a receptors and neutrophils mediate Monoclonal Antibody and by C5a Anaphylatoxin-Induced Ca2+ fetal injury in the antiphospholipid syndrome” .I. Clin. Invest. 112(1 1): 1644-1654. Release” Lab. Invest. 79(10):1287-1297. Shopes (1992) “A Genetically Engineered Human IgG Mutant with Gu et al. (2003) “Neuropilin-l conveys semaphorin and VEGF sig naling during neural and cardiovascular development” Dev Cell Enhanced Cytolytic Activity” .I. Immunol. 148(9):2918-2922. 5(1):45-57. Solomon, et al. (2005) “A Crucial Role for Macrophages in the Heller et al. (1999) “Selection of a C5a receptor antagonist from Pathology of IQB x N Serum-Induced Arthritis” Eur. .I. Immunol. phage libraries attenuating the in?ammatory response in immune 35(10):3064-3073. complex disease and ischemia/reperfusion injury” J Immunol Stevenson, et al. (1989) “A Chimeric Antibody with Dual Fc Regions 163(2):985-994. (bisFabFc) Prepared by Manipulations at the IgG Hinge”Anticancer Homanics (2002) “Knockout and Knockin Mice” Methods inAlcohol Drug Design 3(4):219-230. Related Neuroscience Research, Editor, Liu, Yuan, Chapter 2, pp. Ulmer, et al. (1993) “Heterologous Protection against In?uenza by 3 1-61 . Injection of DNA Encoding a Viral Protein” Science Hopken et al. (1996) “The C5a chemoattractant receptor mediates 259(5102):1745-1749. mucosal defence to infection” Nature 383(6595):86-89. Van Damme, et al. (1992) “Structural and Functional Identi?cation of Hugli et al., The active site of human C4a anaphylatoxin. Mol. Two Human, Tumor-Derived Monocyte Chemotactic Proteins Immunol. 1983;20:637-45. (MCP-2 and MCP-3) Belonging to the Chemokine Family” .I. Exp. International Search Report and Written Opinion issued for PCT/ Med 176(1):59-65. AU2007/001207, dated Nov. 20, 2007 (14 pages). Van Meerten, et al. (2006) “Complement-Induced Cell Death by Kedmi et al. (2003) “Loss of Nicotine-Induced Seizures in Double Rituximab Depends on CD20 Expression Level and Acts Comple Knockout Mice with 015 and [54 Neuronal Nicotinic Acetylcholine mentary to Antibody-Dependent Cellular Cytotoxicity” Clin. Cancer Receptor Subunits De?ciency” Society for Neuroscience, Res. 12(13):4027-4035. Neuroscience 2003 Abstract, Presentation No. 533.12, Nov. 10, Van Riper, et al. (1993) “Characterization and Species Distribution of 2003. High Af?nity GTP-Coupled Receptors for Human Rantes and Kohl (2001) “Anaphylatoxins and infectious and non-infectious Monocyte Chemoattractant Protein 1” .I. Exp. Med. 177(3):851-856. in?ammatory diseases” Mol Immunol 38(2-3): 175-187. Verhoeyen, et al. (1988) “Reshaping Human Antibodies: Grafting an Kuby“Antigens”Immunology, SecondEdition, Ed. Janis Kuby, W.H. Antilysozyme Activity” Science 239(4847): 1534-1536. Freeman and Company, New York, 1994; Chapter 4, pp. 85-108. Vitetta (1993) “Immunotoxins: Magic Bullets or Misguided Mis Kuby “Organization and Expression of Immunoglobulin Genes” siles?” Immunol. Today 14(6):252-259. Immunology, Second Edition, Ed. Janis Kuby, W.H. Freeman and Vitetta, et al. (1987) “Redesigning Nature’s Poisons to Create Anti Company, New York, 1994; Chapter 8, pp. 175-208. Tumor Reagents” Science 238(4830):1098-1104. Labarca et al., “Point mutant mice with hypersensitive .alpha.4 nico Watanabe, et al. (1995) “Analysis of C5a Receptor by Monoclonal tinic receptors show dopaminergic de?cits and increased anxiety,” Antibody” .I. Immunol. Methods 185(1):19-29. PNAS, 2001, 98(5), 2786-2791. Whitfeld, et al. (2007) “Novel mAbs to C5aR 2'” Loop Reverse Layton et al., “Cross-species Receptor Binding Characteristics of Disease in Models of In?ammatory Arthritis” In?amm. Res. Human and Mouse Leukemia Inhibitory Factor Suggest a Complex 56(Suppl. 3):S401. Binding Interaction,” J Biol. Chem., 1994, 269(25), 17048-17055. Williams, et al. (1991) “Introduction ofForeign Genes into Tissues of Lester (2003) “Hypersensitive knockin mouse strains identify recep Living Mice by DNA-Coated Microprojectiles” Proc. Natl. Acad. tors and pathways for nicotine action” Curr Opin Drug Discov Devel Sci. USA 88(7):2726-2730. 6(5):633-639. Wipke & Allen (2001) “Essential Role of Neutrophils in the Initiation Lienenklaus et al. “Cutting Edge: Human anaphylatoxin C4a is a and Progression of a Murine Model of Rheumatoid Arthritis” .I. potent agonist of the guinea pig but not the human C3a receptor” J. Immunol. 167(3):1601-1608. Immunol. 1998;161:2089-93. Wolff, et al. (1993) “Monoclonal Antibody Homodimers: Enhanced Liu et al., “The 01 chain of the IL-2 receptor determines the species Antitumor Activity in Nude Mice” Cancer Res. 53(11):2560-2565. speci?city of high-af?nity IL-2 binding,” Cytokine, 1996, 8(8), 613 Wu & Wu (1987) “Receptor-Mediated In Vitro Gene Transformation 621. by a Soluble DNA Carrier System” .I. Biol. Chem. 262(10):4429 Mosmann et al., “Species-speci?city of T cell stimulating activities 4432. of IL 2 and BSF-l (IL 4): comparison of normal and recombinant, Wu (2003) “Simultaneous Humanization and Af?nity Optimization mouse and human IL 2 and BSF-l (IL 4),” J. Immunol., 1987, 138, of Monoclonal Antibodies” Methods Mol. Biol. 207: 197-212. 1813-1816. US 8,361,468 B2 Page 4 Mukherj ee et al., The role of complement anaphylatoXin C5a in Sato (1999) “Gene trap, gene knockout, gene knock-in, and transgen neurodegradation: Implications in AlZheimer’s Disease. J Neuroim ics in vascular development” Thromb Haemost 82(2):865-869. munol 2000;105(2)124-30. Smith et al., “Species Speci?city of Human and Murine Tumor Muller, Ten years of gene targeting: targeted mouse mutants, from Necrosos factor,” J. Biol. Chem., 1986, 261(32), 14871-14874. vector design to phenotype analysis. Mech. Dev. 1999;82:3-21. Takeuchi,et al., Flp recombinase transgenic mice of C57BL/6 strain Nisonoff “General Structural Properties of Antibodies” Introduction for conditional gene targeting, Biochem Biophys Res Commun. to Molecular Immunology Second Edition, Sinauer Associates, Inc. May 10, 2002;293(3):953-957. Dunderland, MA, 1985; Chapter 2: pp. 7-28. Translation of Of?cial Action issued by Russian Patent Of?ce dated Ohno et al. (1985) “Antigen-binding speci?cities of antibodies are Jan. 17, 2011, Application No. 2009110154/13(013781) (3 pages). primarily determined by seven residues of VH” Proc Natl Acad Sci Wang et al. (2002) “Gain-Of Function Mutation of Human USA 82:2945-2949. Erythropoietin Receptor in Mice Decreases Neointimal Formation” Prince (2005) “Biomarkers for diagnosing and monitoring autoim Blood 11(1 1): Abstract No. 2681. mune diseases” Biomarkers 10(Suppl. 1):544-549. Wong (1999) “Development of C5a Receptor Antagonists” IDrugs Prosser, et al. (2002) “Targeted replacement of rodent CCR2 With the 2(7):686-693. human orthologue CCR2B: A mouse model for in vivo analysis of Woodruff et al. (2001) “Species dependence for binding of small human target-selective small molecule MCP-l receptor antagonists” molecule agonist and antagonists to the C5a receptor on Drug Development Research 55(4): 197-209. polymorphonuclear leukocytes” In?ammation 25(3): 171-177. Roebroek (2003) “Knockin approaches” Methods Mol Biol 209: 187 Woodruff et al. (2002) “Antiarthritic activity of an orally active C5a 200. receptor antagonist against antigen-induced monarticular arthritis in RoZmahel (1997) “Incomplete rescue of cystic ?brosis the rat” Arthritis Rheum 46(9):2476-2485. transmembrane conductance regulator de?cient mice by the human CFTR cDN ” Hum Mol Genet 6(7): 1153-1 162. * cited by examiner US. Patent Jan. 29, 2013 Sheet 1 0f 37 US 8,361,468 B2 wEsww m US. Patent Jan. 29, 2013 Sheet 3 0f 37 US 8,361,468 B2 5252 m 3 mmEgz?mazwwnwmzl wmgm zwmgEzgngmwomwwz m gm mmlmaov zmm>gzgngmwQlowwzu ié 5E5zF5m5zE8s2m E 355E7525N23m2m E $5F9555116 00Eo2